Free Trial

Sol-Gel Technologies (SLGL) Competitors

Sol-Gel Technologies logo
$7.26 +0.25 (+3.62%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SLGL vs. CHEK, DRCT, FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, and SRZN

Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Check-Cap (CHEK), Direct Digital (DRCT), Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), and Surrozen (SRZN).

Sol-Gel Technologies vs. Its Competitors

Check-Cap (NASDAQ:CHEK) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Sol-Gel Technologies has higher revenue and earnings than Check-Cap. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A-$17.57M-$3.00-0.27
Sol-Gel Technologies$11.54M1.76-$10.58M-$4.70-1.55

Check-Cap has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Sol-Gel Technologies has a consensus price target of $40.00, indicating a potential upside of 450.66%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Sol-Gel Technologies
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Check-Cap has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -107.78%. Check-Cap's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Sol-Gel Technologies -107.78%-43.98%-35.28%

In the previous week, Check-Cap had 2 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 2 mentions for Check-Cap and 0 mentions for Sol-Gel Technologies. Check-Cap's average media sentiment score of 0.00 equaled Sol-Gel Technologies'average media sentiment score.

Company Overall Sentiment
Check-Cap Neutral
Sol-Gel Technologies Neutral

Summary

Sol-Gel Technologies beats Check-Cap on 8 of the 14 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLGL vs. The Competition

MetricSol-Gel TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.17M$3.85B$5.53B$8.98B
Dividend YieldN/A1.16%5.25%4.04%
P/E Ratio-1.546.6627.0220.11
Price / Sales1.7610.71431.59122.88
Price / CashN/A6.5336.8257.86
Price / Book0.702.808.075.56
Net Income-$10.58M-$109.62M$3.17B$248.52M
7 Day Performance-0.29%14.75%3.83%5.02%
1 Month Performance2.74%18.38%3.56%6.94%
1 Year Performance-24.33%34.48%34.27%21.32%

Sol-Gel Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLGL
Sol-Gel Technologies
2.6268 of 5 stars
$7.26
+3.6%
$40.00
+450.7%
-13.5%$20.17M$11.54M-1.5450Gap Up
CHEK
Check-Cap
0.4628 of 5 stars
$0.77
+0.7%
N/A-57.8%$4.48MN/A-0.2680
DRCT
Direct Digital
3.4716 of 5 stars
$0.57
+4.6%
$6.00
+961.9%
-84.4%$10.21M$62.29M-0.3260Gap Down
FBRX
Forte Biosciences
2.5487 of 5 stars
$12.93
+5.6%
$61.00
+371.8%
+58,767.9%$80.65MN/A-0.795
CLLS
Cellectis
3.0481 of 5 stars
$1.53
+5.2%
$4.00
+162.3%
-20.3%$80.60M$49.22M-1.77290Gap Down
CLYM
Climb Bio
2.6374 of 5 stars
$1.24
+5.1%
$9.00
+625.8%
N/A$79.74MN/A-0.529Gap Up
CABA
Cabaletta Bio
1.5297 of 5 stars
$1.52
-3.2%
$14.43
+849.2%
-80.0%$79.67MN/A-0.6050
MCRB
Seres Therapeutics
3.5484 of 5 stars
$11.11
+22.1%
$73.67
+563.1%
-40.4%$79.46M$126.32M-2.42330Positive News
High Trading Volume
TCRX
TScan Therapeutics
2.7655 of 5 stars
$1.45
+3.6%
$7.80
+437.9%
-70.8%$79.23M$2.82M-1.33100News Coverage
VNRX
VolitionRx
1.6784 of 5 stars
$0.76
-9.3%
$3.50
+360.5%
+15.3%$78.30M$1.31M-2.1180News Coverage
Analyst Forecast
Gap Up
SRZN
Surrozen
2.3638 of 5 stars
$8.94
-0.9%
$38.50
+330.6%
-21.0%$77.24M$10.65M-0.3680High Trading Volume

Related Companies and Tools


This page (NASDAQ:SLGL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners